Jiangsu Hengrui Medicine Co., Ltd.

This study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and…

This early-phase study tests a new drug called HRS-3005 in 190 adults with B-cell blood cancers (like lymphoma or leukemia) that have returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and get a first look at wheth…

This study tests a new drug called HRS-5041, taken as a pill, combined with other cancer treatments for men with advanced prostate cancer. The goal is to see if the combination is safe and helps control the cancer. About 100 men aged 18 to 80 will take part. The study is currentl…

This study tests a new drug called HRS-6209, taken as a capsule, combined with either letrozole or another drug HRS-2189 in 80 women with breast cancer. The goal is to find a safe dose and see if the combination can shrink tumors. It is an early-stage trial, so the main focus is …

This study tests an experimental drug called SHR-A1904 in 83 people with advanced solid tumors, including stomach and pancreatic cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This study tests whether a radioactive drug called lutetium-177 oxodotreotide, when combined with a standard dose of octreotide, works better than a high dose of octreotide alone for people with advanced neuroendocrine tumors of the gut or pancreas. About 220 adults aged 18-75 wi…

This Phase 3 trial compares a new oral drug, rezvilutamide, against the current standard enzalutamide, both combined with hormone therapy, in 206 men with low-volume metastatic prostate cancer that still responds to hormones. The main goal is to see if rezvilutamide can lower PSA…

This phase 2 trial is testing a new drug, trastuzumab rezetecan, against an existing drug, trastuzumab deruxtecan, in 150 women with a common type of advanced breast cancer (HR-positive, HER2-low). The goal is to see which dose works best to slow cancer growth. Participants must …

This study tests an experimental drug, hetrombopag, to see if it can safely raise platelet counts in cancer patients whose platelets drop too low after chemotherapy. About 150 adults with solid tumors (like lung, breast, or colon cancer) will receive either the drug or a placebo …

This study tests a new drug, HRS-9190, against a standard muscle relaxant used during surgery. About 60 adults having planned surgery will get one of the two drugs. The main goal is to see how fast muscles recover after the drug is stopped. Researchers will also check for side ef…

This study is testing a new drug called SHR-4394 combined with other anti-cancer treatments for men with prostate cancer. The goal is to find the safest dose and see if the combination can lower PSA levels, a key marker of prostate cancer. About 100 men aged 18 to 85 will take pa…

This study tests two new drug combinations for people with advanced non-small cell lung cancer that has a HER2 mutation. The drugs are SHR-A1811 (given by IV) combined with either pyrotinib (a pill) or SHR-1316 (another IV drug). The trial has two parts: first, finding the safest…

This phase 3 trial tests a new drug called SHR-A1811 against standard chemotherapy in 300 people with ovarian, fallopian tube, or primary peritoneal cancer that no longer responds to platinum-based treatment. The goal is to see if the new drug can slow cancer growth and improve s…

This Phase 1 trial tests a new injectable drug called SHR-3167 in 55 adults with type 2 diabetes. The study measures how the drug moves through the body and how well it controls blood sugar. Participants will receive either SHR-3167 or insulin degludec to compare their effects an…

This early-stage trial is testing a new drug called SHR-1049 in 200 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also look …

This phase 2 trial tests an experimental drug called FH-006 combined with other cancer treatments in 200 people with advanced non-small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. Researchers will also determine the best dose for future …

This study tests whether adding a new drug (SHR4640) to a standard gout medication (febuxostat) works better than just increasing the dose of febuxostat alone. About 340 adults with gout and high uric acid who are not well-controlled on 40 mg of febuxostat will take either the co…

This study tests a new drug called HRS-8364 in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose and check how well the drug shrinks tumors. About 282 participants will take part across multiple ce…

This early-stage study tests an experimental drug called HRS-2329 in people with advanced solid tumors that have RAS mutations or amplifications. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 120 participants will take…

This phase II study tests two experimental drugs, HS-20093 and SHR2554, combined with standard hormone therapies in 218 men with metastatic prostate cancer. The goal is to see if these combos are safe and can lower PSA levels or slow the cancer's spread. Participants must have ad…

This study tests a new drug called SHR0302, given as a tablet and a gel, for people with non-segmental vitiligo. The goal is to see if it can safely and effectively bring back skin color. About 176 adults aged 18 to 75 will take part, and some will receive a placebo to compare re…

This study tests a new drug, HRS-4357, against current standard treatments for men with a specific type of advanced prostate cancer (PSMA-positive, castration-resistant) that has spread. About 370 men will be randomly assigned to receive either HRS-4357 or a standard therapy. The…

This phase 3 trial is testing a new drug called SHR-A1811 against a standard chemotherapy combination for women with early-stage or locally advanced HER2-positive breast cancer. About 740 participants will receive either the new drug or standard treatment before surgery. The main…

This study tests a new drug, SHR-A1811, against standard treatments for people with advanced or metastatic non-small cell lung cancer that has a specific change in the HER2 gene. About 300 participants who have not had prior treatment for advanced disease will be enrolled. The go…

This study tests whether a combination of two drugs (camrelizumab and apatinib) can help people with advanced stomach or gastroesophageal junction cancer live longer compared to standard chemotherapy. The trial includes 550 adults whose cancer progressed after first-line platinum…

This phase 3 trial compares a new drug called SHR2554 to an existing drug, chidamide, in 130 people with a rare type of lymphoma (PTCL) that has come back or not responded to at least one prior treatment. The main goal is to see if SHR2554 can delay cancer growth better than chid…

This study tests a new drug called HRS-4508 in people with advanced non-small cell lung cancer that has not responded to or cannot tolerate standard treatments. About 120 participants will take the drug as a tablet. Researchers will check how safe it is and whether it shrinks tum…

This Phase 2 trial is testing a new drug called HRS-4508, given as a tablet, together with other anticancer drugs (SHR-A1811 and/or Adebrelimab) in 100 adults with advanced non-small cell lung cancer that has not responded to standard treatments. The main goals are to check safet…

This Phase III trial is testing whether a new combination of drugs (irinotecan liposome, oxaliplatin, 5-fluorouracil, and calcium folinate) works better than the current standard treatment (nab-paclitaxel plus gemcitabine) for people with metastatic pancreatic cancer who haven't …

This study tests an experimental drug called FH-006 in 200 people with advanced solid tumors that have not responded to standard treatments. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive FH-006 by IV every 2 or 3…

This early-stage trial tests a new drug called HRS-6093 in people with advanced solid tumors that have a specific mutation called KRAS G12D. The study aims to find a safe dose and see how the drug affects the body. About 153 participants will be enrolled across multiple centers.

This study tests a new drug called HRS-6768 in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: the first checks safety and the best dose, and the second looks at whether the drug can slow tumor growth. About 84 participa…

This study tests a drug called herombopag in people with chronic liver disease who have low platelet counts and need surgery. The goal is to see if the drug can safely raise platelet levels enough to reduce bleeding risk during the procedure. About 101 adults with mild to moderat…

This Phase 2 trial is testing a drug called SHR-A1811 in 60 women with HER2-expressing cervical cancer that has spread or returned after standard treatments. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The main goal is to see …

This phase 2 trial is testing whether combining the experimental drug SHR2554 with other anti-tumor treatments can safely shrink tumors in people with advanced non-small cell lung cancer that cannot be removed by surgery. About 200 participants will receive one of three drug comb…

This early-stage study tests a new drug called HRS-7172 in people with advanced solid tumors that have RAS mutations or amplifications. The main goals are to check safety, find the best dose, and see how the body processes the drug. About 120 adults aged 18-75 with good organ fun…

This study tests a new drug called HRS-4642 combined with other anti-cancer agents in people with advanced solid tumors that have a KRAS G12D mutation. The trial has two phases: first to find the safest dose, then to see how well the combination works. About 118 adults aged 18-75…

This Phase 2 trial is testing whether a new targeted drug called SHR2554, taken as a tablet, can be safely combined with other anti-cancer injections to treat advanced stomach or gastroesophageal junction cancer. The study will enroll 351 adults whose cancer has spread or cannot …

This study tests a new drug called HRS-1167 combined with two standard medications (abiraterone and prednisone) in men with metastatic prostate cancer. The goal is to see if the combination is safe, tolerable, and effective. About 66 participants will be enrolled across multiple …

This study tests a long-acting painkiller (bupivacaine liposome) injected near the spine to control pain after lung surgery. About 96 adults having a specific type of lung surgery will receive either the new drug or a standard painkiller. The goal is to see if the new drug provid…

This study tests a new sedative called tegileridine fumarate in 120 ICU patients who need a breathing machine for at least two days. The goal is to see if it keeps patients comfortable and calm better than a standard sedative. Researchers will measure how often the drug works and…

This study looks at a painkiller called bupivacaine liposome injection, given during surgery to help control pain afterward. It involves 232 children aged 6 to 17 having orthopedic (bone) surgery. The goal is to see if it safely reduces pain and the need for stronger opioid pain …

This early-stage study tests different doses of an experimental diabetes drug called SHR-3167 in 60 healthy adults aged 18 to 55. The goal is to measure how much of the drug gets into the blood and how safe it is, not to treat any disease. Participants will receive a single injec…

This early-stage study tests the safety and tolerability of a new injectable drug called HRS-2183 in 42 healthy Chinese adults aged 18-45. Participants receive either a single dose or multiple doses to see how the drug moves through the body and if it causes any side effects. Thi…